Proced/lres to 
Introduction
'TI le use of dissolution testing as a quality control tool grew explosive ly in the decade of the 1970s. Dur- oral , so lid dosage forms and exte nded re leose ora l forms have been published extensively in the US [2] [3] [4] [5] [6] [7] and Europe [8, 9] . The content of the first report which dea lt with conventional , oral soli d dosage forms was subjected to further scrutin y through FDA-sponso red extra-mura l stud ies.
These stud ies tested the bioavailabi lity of a se ri es of tablets manufacnlred with differ- drugs as I ) highly permeable/ hi ghly solubl e 2) hi ghl y permeable/poorly soluble; poorly permeable/highly so lu ble or 3) poorly permeable/poorly soluble. A somewhat arbitrary definition of so lubil ity was establi s hed bas ed on the typical vo lum e ingested at the time a dosage form is administered, e.g., 250 mL. If the tota l dose of drug is soluble in <250 mL, it is co nsidered hi g hl y so lubl e.
Drugs with an extent of absorption of >90% in the intestinal
tract are considered to be highly permeab le. Subsequent to the Workshop Report, add itio nal clarity on tllis topic was provided in an article whi ch describes the theo r etica l ba sis of this approach flO].
Usi ng these definitions it is s<.lfe to ass um e that drugs that satisfy category I are not subject to bioavailability issues and their dissolution profile is expected to be reflected in comp lete and rapid absorption and bioavailability. For such drugs, a single Ll order to be assured that the drug product is performing re producibl y during sca le-up, the disso lution profile of the drug product shou ld be thoro ugh ly in vestigated and co ntrasted to ea rli er (s maller) batclles . It is suggested that the profile be determined (e.g. 
